Detalhe da pesquisa
1.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
N Engl J Med
; 389(18): 1672-1684, 2023 Nov 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37870974
2.
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Br J Clin Pharmacol
; 89(5): 1601-1616, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36454221
3.
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.
Curr Ther Res Clin Exp
; 95: 100640, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34484473
4.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artigo
Inglês
| MEDLINE | ID: mdl-27959700
5.
Driving in Parkinson's disease: a retrospective study of driving and mobility assessments.
Age Ageing
; 49(6): 1097-1101, 2020 10 23.
Artigo
Inglês
| MEDLINE | ID: mdl-32585014
6.
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
Cancer
; 125(6): 892-901, 2019 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30512189
7.
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.
J Pharmacol Exp Ther
; 369(2): 291-299, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30872388
8.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Br J Cancer
; 119(9): 1075-1085, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30353045
9.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 17(12): 1643-1652, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-27751847
10.
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Br J Cancer
; 115(11): 1313-1320, 2016 Nov 22.
Artigo
Inglês
| MEDLINE | ID: mdl-27824811
11.
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Breast Cancer Res Treat
; 160(1): 91-99, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27654971
12.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Gynecol Oncol
; 140(2): 199-203, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26723501
13.
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
BMC Cancer
; 15: 467, 2015 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26059332
14.
Utility values in health technology assessments: a statistician's perspective.
Pharm Stat
; 13(3): 184-95, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24692364
15.
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Clin Cancer Res
; 30(4): 824-835, 2024 02 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37801329
16.
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
J Thorac Oncol
; 18(5): 657-663, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36841540
17.
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
Lung Cancer
; 178: 87-95, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36806898
18.
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
Clin Pharmacol Ther
; 114(6): 1375-1386, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37777827
19.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
J Thorac Oncol
; 18(1): 106-119, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36240972
20.
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol
; 18(11): 1594-1606, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37390980